The role of LRRK2 in cell signalling.
暂无分享,去创建一个
[1] M. Cookson,et al. Proteomic analysis reveals co-ordinated alterations in protein synthesis and degradation pathways in LRRK2 knockout mice , 2018, Human molecular genetics.
[2] C. Gloeckner,et al. Regulation of LRRK2: insights from structural and biochemical analysis , 2018, Biological chemistry.
[3] James E. Tomkins,et al. Comparative Protein Interaction Network Analysis Identifies Shared and Distinct Functions for the Human ROCO Proteins , 2018, Proteomics.
[4] Le-Ming Shi,et al. The kinase LRRK2 is differently expressed in chronic rhinosinusitis with and without nasal polyps , 2018, Clinical and Translational Allergy.
[5] R. Heumann,et al. The role of (auto)-phosphorylation in the complex activation mechanism of LRRK2 , 2018, Biological chemistry.
[6] P. Ricciardi-Castagnoli,et al. Leucine-Rich Repeat Kinase 2 Controls the Ca2+/Nuclear Factor of Activated T Cells/IL-2 Pathway during Aspergillus Non-Canonical Autophagy in Dendritic Cells , 2018, Front. Immunol..
[7] V. Baekelandt,et al. LRRK2 Phosphorylation: Behind the Scenes , 2018, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[8] M. Cookson,et al. LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network , 2018, Human molecular genetics.
[9] Judy H. Cho,et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease , 2018, Science Translational Medicine.
[10] S. Pfeffer,et al. Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase , 2017, The EMBO journal.
[11] A. West. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease , 2017, Experimental Neurology.
[12] T. Gasser,et al. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils , 2017, The Biochemical journal.
[13] M. Mann,et al. Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase , 2017, The Biochemical journal.
[14] Matthias Mann,et al. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis , 2017, eLife.
[15] P. V. van Haastert,et al. A homologue of the Parkinson’s disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover , 2017, Nature Communications.
[16] M. Nalls,et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.
[17] E. Arenas,et al. A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway , 2017, Molecular Neurodegeneration.
[18] A. Bhardwaj,et al. In situ click chemistry generation of cyclooxygenase-2 inhibitors , 2017, Nature Communications.
[19] S. Hilfiker,et al. Cellular effects mediated by pathogenic LRRK2: homing in on Rab-mediated processes. , 2017, Biochemical Society transactions.
[20] L. Bubacco,et al. Cross-talk between LRRK2 and PKA: implication for Parkinson's disease? , 2017, Biochemical Society transactions.
[21] S. Hilfiker,et al. LRRK2: from kinase to GTPase to microtubules and back. , 2017, Biochemical Society transactions.
[22] W. James,et al. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease , 2017, Biochemical Society transactions.
[23] M. Islam,et al. Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation. , 2017, Biochemical Society transactions.
[24] A. Pitsillides,et al. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling , 2017, Molecular Neurodegeneration.
[25] David S. Lorberbaum,et al. Genetic evidence that Nkx2.2 acts primarily downstream of Neurog3 in pancreatic endocrine lineage development , 2017, eLife.
[26] S. Terheyden,et al. The unconventional G-protein cycle of LRRK2 and Roco proteins. , 2016, Biochemical Society transactions.
[27] D. Berwick,et al. L'RRK de Triomphe: a solution for LRRK2 GTPase activity? , 2016, Biochemical Society transactions.
[28] R. Uitti,et al. Cancer in Parkinson's disease. , 2016, Parkinsonism & related disorders.
[29] K. Harvey,et al. Back to the tubule: microtubule dynamics in Parkinson’s disease , 2016, Cellular and Molecular Life Sciences.
[30] A. Reith,et al. Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors , 2016, The Biochemical journal.
[31] F. Staal,et al. Wnt Signaling as Master Regulator of T-Lymphocyte Responses: Implications for Transplant Therapy. , 2016, Transplantation.
[32] E. Gerhardt,et al. LRRK2 Promotes Tau Accumulation, Aggregation and Release , 2015, Molecular Neurobiology.
[33] C. Blackstone,et al. Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity , 2016, Front. Mol. Neurosci..
[34] Y. Shu,et al. Parkinson-Related LRRK2 Mutation R1628P Enables Cdk5 Phosphorylation of LRRK2 and Upregulates Its Kinase Activity , 2016, PloS one.
[35] Matthias Mann,et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases , 2016, eLife.
[36] L. Bubacco,et al. Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells , 2015, Journal of Neuroinflammation.
[37] M. Cookson,et al. Leucine‐rich repeat kinase 2 interacts with p21‐activated kinase 6 to control neurite complexity in mammalian brain , 2015, Journal of neurochemistry.
[38] G. Shaw,et al. Physiologically relevant factors influence tau phosphorylation by leucine‐rich repeat kinase 2 , 2015, Journal of neuroscience research.
[39] S. Gerber,et al. LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5. , 2015, Biochemistry.
[40] Chia-Lung Chuang,et al. Genetic dissection reveals that Akt is the critical kinase downstream of LRRK2 to phosphorylate and inhibit FOXO1, and promotes neuron survival. , 2014, Human molecular genetics.
[41] A. Whitworth,et al. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations , 2014, Nature Communications.
[42] Heung-Chin Cheng,et al. Prediction of the Repeat Domain Structures and Impact of Parkinsonism‐Associated Variations on Structure and Function of all Functional Domains of Leucine‐Rich Repeat Kinase 2 (LRRK2) , 2014, Human mutation.
[43] L. Bubacco,et al. LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease? , 2014, Journal of Neuroinflammation.
[44] Suneil K. Kalia,et al. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease , 2014, Proceedings of the National Academy of Sciences.
[45] Fumitaka Kawakami,et al. Leucine‐rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase‐3β , 2014, The FEBS journal.
[46] H. Cai,et al. A Direct Interaction between Leucine-rich Repeat Kinase 2 and Specific β-Tubulin Isoforms Regulates Tubulin Acetylation* , 2013, The Journal of Biological Chemistry.
[47] D. Berwick,et al. The regulation and deregulation of Wnt signaling by PARK genes in health and disease , 2013, Journal of molecular cell biology.
[48] C. Niehrs. The complex world of WNT receptor signalling , 2012, Nature Reviews Molecular Cell Biology.
[49] Kirsten Harvey,et al. The importance of Wnt signalling for neurodegeneration in Parkinson's disease. , 2012, Biochemical Society transactions.
[50] D. Berwick,et al. LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6 , 2012, Human molecular genetics.
[51] Patrick G. A. Pedrioli,et al. The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling , 2012, PloS one.
[52] T. Yeh,et al. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD , 2012, Cell Death and Differentiation.
[53] F. Obata,et al. LRRK2 Phosphorylates Tubulin-Associated Tau but Not the Free Molecule: LRRK2-Mediated Regulation of the Tau-Tubulin Association and Neurite Outgrowth , 2012, PloS one.
[54] Dong-mei Zhao,et al. Regulation of mature T cell responses by the Wnt signaling pathway , 2012, Annals of the New York Academy of Sciences.
[55] J. Goldberg,et al. Multiple transcription factor families regulate axon growth and regeneration , 2011, Developmental neurobiology.
[56] Wei Lu,et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease , 2011, Nature Immunology.
[57] Zhihui Xie,et al. Nuclear Factor of Activated T Cells (NFAT) Proteins Repress Canonical Wnt Signaling via Its Interaction with Dishevelled (Dvl) Protein and Participate in Regulating Neural Progenitor Cell Proliferation and Differentiation* , 2011, The Journal of Biological Chemistry.
[58] D. Berwick,et al. LRRK2 signaling pathways: the key to unlocking neurodegeneration? , 2011, Trends in cell biology.
[59] Qing Jun Wang,et al. Phosphorylation-Dependent 14-3-3 Binding to LRRK2 Is Impaired by Common Mutations of Familial Parkinson's Disease , 2011, PloS one.
[60] Philip L De Jager,et al. Parkinson's disease: genetics and pathogenesis. , 2011, Annual review of pathology.
[61] Sebastián M. Real,et al. E2F1 Regulates Cellular Growth by mTORC1 Signaling , 2011, PloS one.
[62] C. Chien,et al. LRRK2 G2019S Mutation Induces Dendrite Degeneration through Mislocalization and Phosphorylation of Tau by Recruiting Autoactivated GSK3β , 2010, The Journal of Neuroscience.
[63] N. Restifo,et al. Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy , 2010, Clinical Cancer Research.
[64] A. Prescott,et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization , 2010, The Biochemical journal.
[65] X. Li,et al. Reevaluation of Phosphorylation Sites in the Parkinson Disease-associated Leucine-rich Repeat Kinase 2* , 2010, The Journal of Biological Chemistry.
[66] Z. Berger,et al. Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. , 2010, Biochemistry.
[67] Hideki Yamamoto,et al. Wnt5a regulates distinct signalling pathways by binding to Frizzled2 , 2010, The EMBO journal.
[68] Rosa M. Sancho,et al. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways , 2009, Human molecular genetics.
[69] M. Cookson,et al. The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation* , 2008, Journal of Biological Chemistry.
[70] R. Nichols,et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. , 2007, The Biochemical journal.
[71] Matthew J. Farrer,et al. LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.
[72] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[73] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[74] P. V. van Haastert,et al. Roc, a Ras/GTPase domain in complex proteins. , 2003, Biochimica et biophysica acta.
[75] N. Dzamko,et al. LRRK2 and the Immune System. , 2017, Advances in neurobiology.
[76] D. Re,et al. LRRK2 and the "LRRKtosome" at the Crossroads of Programmed Cell Death: Clues from RIP Kinase Relatives. , 2017, Advances in neurobiology.
[77] F. Staal,et al. Wnt signaling as master regulator of T lymphocyte responses: implications for transplant therapy. , 2016, Transplantation.
[78] A. Mirelman,et al. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. , 2015, JAMA neurology.